Stock Track | Alumis Inc. Soars 94.46% in Pre-Market After Positive Phase 3 Psoriasis Drug Results

Stock Track01-06

Alumis Inc. (ALMS) shares surged 94.46% in pre-market trading on Tuesday following the announcement of positive Phase 3 trial results for its experimental drug, envudeucitinib, in treating moderate-to-severe plaque psoriasis.

The drug met all primary and secondary endpoints in two late-stage trials, with approximately 65% of patients achieving significant skin clearance (PASI 90) and over 40% achieving complete clearance (PASI 100) after 24 weeks. The safety profile was consistent with earlier studies, and the company plans to submit a New Drug Application (NDA) to the FDA in the second half of 2026.

Analysts noted that envudeucitinib's efficacy approaches that of top-selling injectable psoriasis treatments, positioning it as a potential leader in the oral TYK2 inhibitor class. If approved, it could compete with Bristol Myers Squibb's Sotyktu, offering a new treatment option for over 8 million U.S. psoriasis patients.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1170812989?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-06 21:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1170812989","market":"hk","top_or_hot":-1,"title":"Stock Track | Alumis Inc. Soars 94.46% in Pre-Market After Positive Phase 3 Psoriasis Drug Results","media":"Stock Track","content":"<p>Alumis Inc. (ALMS) shares surged 94.46% in pre-market trading on Tuesday following the announcement of positive Phase 3 trial results for its experimental drug, envudeucitinib, in treating moderate-to-severe plaque psoriasis.</p><p>The drug met all primary and secondary endpoints in two late-stage trials, with approximately 65% of patients achieving significant skin clearance (PASI 90) and over 40% achieving complete clearance (PASI 100) after 24 weeks. The safety profile was consistent with earlier studies, and the company plans to submit a New Drug Application (NDA) to the FDA in the second half of 2026.</p><p>Analysts noted that envudeucitinib's efficacy approaches that of top-selling injectable psoriasis treatments, positioning it as a potential leader in the oral TYK2 inhibitor class. If approved, it could compete with Bristol Myers Squibb's Sotyktu, offering a new treatment option for over 8 million U.S. psoriasis patients.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Alumis Inc. Soars 94.46% in Pre-Market After Positive Phase 3 Psoriasis Drug Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Alumis Inc. Soars 94.46% in Pre-Market After Positive Phase 3 Psoriasis Drug Results\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-01-06 21:02</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Alumis Inc. (ALMS) shares surged 94.46% in pre-market trading on Tuesday following the announcement of positive Phase 3 trial results for its experimental drug, envudeucitinib, in treating moderate-to-severe plaque psoriasis.</p><p>The drug met all primary and secondary endpoints in two late-stage trials, with approximately 65% of patients achieving significant skin clearance (PASI 90) and over 40% achieving complete clearance (PASI 100) after 24 weeks. The safety profile was consistent with earlier studies, and the company plans to submit a New Drug Application (NDA) to the FDA in the second half of 2026.</p><p>Analysts noted that envudeucitinib's efficacy approaches that of top-selling injectable psoriasis treatments, positioning it as a potential leader in the oral TYK2 inhibitor class. If approved, it could compete with Bristol Myers Squibb's Sotyktu, offering a new treatment option for over 8 million U.S. psoriasis patients.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ALMS","symbol_name":"Alumis Inc.","start_time":0,"source_url":"","article_id":"1170812989","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1170812989","pubTimestamp":1767704550,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Alumis Inc. (ALMS) shares surged 94.46% in pre-market trading on Tuesday following the announcement of positive Phase 3 trial results for its experimental drug, envudeucitinib, in treating...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ALMS":"Alumis Inc."},"translate_title":"股票追踪|Alumis Inc.在银屑病3期药物结果积极后盘前飙升94.46%","themeId":"ff7d18fe305d0508493cad3a6b784395","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ALMS":1},"content_text":"Alumis Inc. (ALMS) shares surged 94.46% in pre-market trading on Tuesday following the announcement of positive Phase 3 trial results for its experimental drug, envudeucitinib, in treating moderate-to-severe plaque psoriasis.The drug met all primary and secondary endpoints in two late-stage trials, with approximately 65% of patients achieving significant skin clearance (PASI 90) and over 40% achieving complete clearance (PASI 100) after 24 weeks. The safety profile was consistent with earlier studies, and the company plans to submit a New Drug Application (NDA) to the FDA in the second half of 2026.Analysts noted that envudeucitinib's efficacy approaches that of top-selling injectable psoriasis treatments, positioning it as a potential leader in the oral TYK2 inhibitor class. If approved, it could compete with Bristol Myers Squibb's Sotyktu, offering a new treatment option for over 8 million U.S. psoriasis patients.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1170812989","isCrawlerRequest":true}